## Jeptha P Curtis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5684526/publications.pdf

Version: 2024-02-01

45317 47006 9,167 184 47 90 citations h-index g-index papers 187 187 187 10491 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Obesity Paradox. Archives of Internal Medicine, 2005, 165, 55.	3.8	702
2	Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCI. New England Journal of Medicine, 2013, 369, 901-909.	27.0	609
3	The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. Journal of the American College of Cardiology, 2003, 42, 736-742.	2.8	445
4	Recent National Trends in Readmission Rates After Heart Failure Hospitalization. Circulation: Heart Failure, 2010, 3, 97-103.	3.9	373
5	The National Cardiovascular Data Registry (NCDR) Data Quality Brief. Journal of the American College of Cardiology, 2012, 60, 1484-1488.	2.8	324
6	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2020, 323, 734.	7.4	260
7	The NCDR Left Atrial Appendage Occlusion Registry. Journal of the American College of Cardiology, 2020, 75, 1503-1518.	2.8	237
8	Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2015, 314, 2045.	7.4	212
9	Non–Evidence-Based ICD Implantations in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 43.	7.4	207
10	Trends in U.S. Cardiovascular Care. Journal of the American College of Cardiology, 2017, 69, 1427-1450.	2.8	198
11	The Pre-Hospital Electrocardiogram and Time to Reperfusion in Patients With Acute Myocardial Infarction, 2000–2002. Journal of the American College of Cardiology, 2006, 47, 1544-1552.	2.8	189
12	Association of Physician Certification and Outcomes Among Patients Receiving an Implantable Cardioverter-Defibrillator. JAMA - Journal of the American Medical Association, 2009, 301, 1661.	7.4	161
13	Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants. Circulation, 2014, 130, 1037-1043.	1.6	160
14	Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2011, 306, 1338.	7.4	158
15	The Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 420-426.	2.8	149
16	Review of the Registry's Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure. Heart Rhythm, 2010, 7, 1340-1345.	0.7	146
17	Cardiovascular Care Facts. Journal of the American College of Cardiology, 2013, 62, 1931-1947.	2.8	135
18	All-Cause Readmission and Repeat Revascularization After Percutaneous Coronary Intervention in a Cohort of Medicare Patients. Journal of the American College of Cardiology, 2009, 54, 903-907.	2.8	134

#	Article	IF	CITATIONS
19	Incidence and Predictors of Perioperative Complications With Transvenous Lead Extractions. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e004768.	4.8	128
20	Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. JAMA Cardiology, 2016, 1, 900.	6.1	127
21	Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014. JAMA - Journal of the American Medical Association, 2017, 318, 1035.	7.4	111
22	Use of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2015, 132, 1243-1251.	1.6	100
23	Factors Associated With 30-Day Readmission Rates After Percutaneous Coronary Intervention. Archives of Internal Medicine, 2012, 172, 112.	3.8	98
24	Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. Circulation, 2012, 125, 57-64.	1.6	94
25	Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT. Journal of the American College of Cardiology, 2014, 64, 887-894.	2.8	85
26	Review of the ICD Registry's Third Year, Expansion to include Lead Data and Pediatric ICD Procedures, and Role for Measuring Performance. Heart Rhythm, 2009, 6, 1397-1401.	0.7	81
27	Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation. Circulation, 2011, 123, 2069-2076.	1.6	79
28	Seattle Heart Failure and Proportional RiskÂModels Predict Benefit From ImplantableÂCardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 69, 2606-2618.	2.8	79
29	Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: Evidence from the NCDR®. American Heart Journal, 2014, 167, 376-383.	2.7	76
30	Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population. European Heart Journal, 2020, 41, 870-878.	2.2	76
31	Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ: British Medical Journal, 2003, 327, 1322-1323.	2.3	75
32	The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation From the Implantable Cardioverter-Defibrillator Registry. Journal of the American College of Cardiology, 2010, 56, 1133-1139.	2.8	74
33	Patterns and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2014, 311, 836.	7.4	72
34	Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). American Heart Journal, 2015, 170, 330-338.	2.7	72
35	Coronary Catheterization and Percutaneous Coronary Intervention in China. JAMA Internal Medicine, 2016, 176, 512.	5.1	72
36	Review of the Registry's Second Year, Data Collected, and Plans to Add Lead and Pediatric ICD Procedures. Heart Rhythm, 2008, 5, 1359-1363.	0.7	71

#	Article	IF	CITATIONS
37	Effect of Hospital Volume on Outcomes of Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 116, 587-594.	1.6	70
38	Use and Effectiveness of Intra-Aortic Balloon Pumps Among Patients Undergoing High Risk Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 21-30.	2.2	68
39	Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation. Annals of Internal Medicine, 2016, 165, 20.	3.9	64
40	Comparison of Machine Learning Methods With National Cardiovascular Data Registry Models for Prediction of Risk of Bleeding After Percutaneous Coronary Intervention. JAMA Network Open, 2019, 2, e196835.	5.9	60
41	Cardiac Resynchronization Therapy in Women Versus Men. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S4-11.	2.2	59
42	National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65ÂYears in the United States (1999 to 2010). American Journal of Cardiology, 2015, 116, 1436-1442.	1.6	57
43	Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents for Patients With Isolated Proximal Left Anterior Descending Disease. Journal of the American College of Cardiology, 2014, 64, 2717-2726.	2.8	56
44	Use of Remote Monitoring Is Associated With Lower Risk of Adverse Outcomes Among Patients With Implanted Cardiac Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1173-1180.	4.8	56
45	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open, 2021, 4, e2037748.	5.9	54
46	Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion. JACC: Clinical Electrophysiology, 2022, 8, 766-778.	3.2	54
47	The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Classification System. Circulation, 2015, 132, 1710-1718.	1.6	52
48	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	3.9	49
49	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiology, 2021, 6, 1275.	6.1	49
50	Executive Summary: Trends in U.S. Cardiovascular Care. Journal of the American College of Cardiology, 2017, 69, 1424-1426.	2.8	48
51	Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 550-559.	2.2	47
52	Gender differences in physical activity following acute myocardial infarction in adults: A prospective, observational study. European Journal of Preventive Cardiology, 2017, 24, 192-203.	1.8	47
53	Modeling Major Adverse Outcomes of Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Catheterization. Circulation, 2017, 136, 2009-2019.	1.6	46
54	Influence of Age on Perioperative Complications Among Patients Undergoing Implantable Cardioverter-Defibrillators for Primary Prevention in the United States. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 549-556.	2.2	45

#	Article	IF	Citations
55	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 793-799.	4.8	45
56	Regional Variation in the Use of Implantable Cardioverter-Defibrillators for Primary Prevention. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 114-121.	2.2	44
57	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation, 2018, 138, 1210-1220.	1.6	42
58	Antithrombotic Therapy After LeftÂAtrialÂAppendage Occlusion in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1785-1798.	2.8	42
59	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	3.9	41
60	Prevalence and Predictors of Off-Label Use of Cardiac Resynchronization Therapy in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. Journal of the American College of Cardiology, 2010, 56, 766-773.	2.8	39
61	Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1092-1100.	4.8	38
62	Ventricular septal rupture complicating acute myocardial infarction: Incidence, treatment, and outcomes among medicare beneficiaries 1999–2014. Catheterization and Cardiovascular Interventions, 2018, 92, 1104-1115.	1.7	38
63	Developing a Risk Model for In-Hospital Adverse Events Following Implantable Cardioverter-Defibrillator Implantation. Journal of the American College of Cardiology, 2014, 63, 788-796.	2.8	37
64	Predicting In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 216-229.	2.8	36
65	Variation in Use of Dual-Chamber Implantable Cardioverter-Defibrillators. Archives of Internal Medicine, 2012, 172, 634.	3.8	34
66	Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator. Circulation, 2018, 137, 2463-2477.	1.6	34
67	Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. JAMA Internal Medicine, 2018, 178, 239.	5.1	34
68	Safety of Pacemaker Implantation in Nonagenarians. Circulation, 2013, 127, 1453-1465.	1.6	32
69	Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation. Journal of the American College of Cardiology, 2014, 64, 256-264.	2.8	32
70	Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Placement in the United States, 2006–2010. Circulation, 2014, 130, 845-853.	1.6	32
71	Institutional Variation in Quality of Cardiovascular Implantable Electronic Device Implantation. Annals of Internal Medicine, 2019, 171, 309.	3.9	32
72	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	4.1	30

#	Article	IF	CITATIONS
73	Complications Associated With Implantable Cardioverter Defibrillators in Adults With Congenital Heart Disease or Left Ventricular Noncompaction Cardiomyopathy (From the NCDR® Implantable) Tj ETQq1 1 (	).7 <b>8.4</b> 314	rgBI9/Overlo
74	Impact of Hospital Volume on Outcomes of Lower Extremity Endovascular Interventions (Insights) Tj ETQq0 0 0	rgBT/Ove	rlo၄ <u>k</u> 10 Tf 50
75	Industry Payments to Cardiologists. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005016.	2.2	28
76	State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States. American Journal of Cardiology, 2015, 115, 1494-1501.	1.6	27
77	Comparison of Intermediate-Term Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stents for Patients ≥75ÂYears of Age. American Journal of Cardiology, 2014, 113, 803-808.	1.6	26
78	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. Journal of the American College of Cardiology, 2015, 66, 2618-2629.	2.8	26
79	Readmissions After Carotid Artery Revascularization in the Medicare Population. Journal of the American College of Cardiology, 2015, 65, 1398-1408.	2.8	26
80	Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. JAMA - Journal of the American Medical Association, 2020, 324, 1755.	7.4	26
81	Outcomes 1 Year After Implantable Cardioverter–Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	25
82	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. American Heart Journal, 2019, 212, 64-71.	2.7	23
83	Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic) Tj ETQq1 1 0.7	7848 <b>&amp;</b> 4 rg	BT <b>⊉</b> ⊘verloc₹
84	Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay VersusÂRight Bundle Branch Block. Journal of the American College of Cardiology, 2019, 73, 3082-3099.	2.8	21
85	Acute Kidney Injury Among Older Patients Undergoing Coronary Angiography for Acute Myocardial Infarction: The SILVER-AMI Study. American Journal of Medicine, 2019, 132, e817-e826.	1.5	21
86	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Internal Medicine, 2020, 180, 1317.	5.1	21
87	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLoS ONE, 2020, 15, e0238829.	2.5	21
88	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 926-934.	3.9	20
89	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006589.	2.2	20
90	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation, 2022, 145, 97-106.	1.6	20

#	Article	IF	Citations
91	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	2.2	19
92	Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States. JACC: Cardiovascular Interventions, 2022, 15, 741-750.	2.9	19
93	A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. American Heart Journal, 2015, 170, 281-289.e2.	2.7	18
94	Predicting Length of Stay and the Need for Postacute Care After Acute Myocardial Infarction to Improve Healthcare Efficiency. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004635.	2.2	18
95	Clinical Model to Predict 90-Day Risk of Readmission After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004788.	2.2	18
96	Transfer Rates From Nonprocedure Hospitals After Initial Admission and Outcomes Among Elderly Patients With Acute Myocardial Infarction. JAMA Internal Medicine, 2014, 174, 213.	5.1	17
97	Does Age Influence Cardiac Resynchronization Therapy Use andÂOutcome?. JACC: Heart Failure, 2015, 3, 497-504.	4.1	17
98	Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: An economic model based on the PREDICT RM database. Journal of Cardiovascular Electrophysiology, 2019, 30, 1066-1077.	1.7	17
99	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e008231.	3.9	17
100	Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator. JAMA Cardiology, 2017, 2, 561.	6.1	16
101	Contemporary Trends, Predictors and Outcomes of Perforation During Percutaneous Coronary Intervention (From the NCDR Cath PCI Registry). American Journal of Cardiology, 2020, 130, 37-45.	1.6	16
102	The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. Journal of Cardiac Failure, 2004, 10, 9-14.	1.7	15
103	The National Cardiovascular Data Registry Data Quality Program 2020. Journal of the American College of Cardiology, 2022, 79, 1704-1712.	2.8	15
104	Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015. JAMA - Journal of the American Medical Association, 2018, 320, 63.	7.4	14
105	Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. Circulation: Cardiovascular Interventions, 2022, 15, .	3.9	14
106	Variation among hospitals in selection of higher-cost, "higher-tech,―implantable cardioverter-defibrillators: Data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry. American Heart Journal, 2013, 165, 1015-1023.e2.	2.7	13
107	Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. American Journal of Cardiology, 2014, 113, 2052-2056.	1.6	13
108	In-Hospital Complications Associated With Reoperations of Implantable Cardioverter Defibrillators. American Journal of Cardiology, 2014, 114, 419-426.	1.6	13

#	Article	lF	CITATIONS
109	Association of Physician Certification in Interventional Cardiology With In-Hospital Outcomes of Percutaneous Coronary Intervention. Circulation, 2015, 132, 1816-1824.	1.6	13
110	Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. Heart Rhythm, 2019, 16, 733-740.	0.7	13
111	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. American Journal of Cardiology, 2020, 133, 116-125.	1.6	13
112	Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. PLoS ONE, 2015, 10, e0138251.	2.5	13
113	Procedure timing as a predictor of inhospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. American Heart Journal, 2015, 169, 45-52.e3.	2.7	12
114	Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm, 2018, 15, 847-854.	0.7	12
115	Body mass index and outcomes of cardiac resynchronization with implantable cardioverterâ€defibrillator therapy in older patients with heart failure. European Journal of Heart Failure, 2019, 21, 1093-1102.	7.1	12
116	The Prognostic Value of Vasodilator Myocardial Perfusion Imaging in Octogenarians. The American Journal of Geriatric Cardiology, 2004, 13, 239-245.	0.6	11
117	Development of 2 Registry-Based Risk Models Suitable for Characterizing Hospital Performance on 30-Day All-Cause Mortality Rates Among Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 628-637.	2.2	11
118	Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy. Journal of the American Heart Association, 2014, 3, e000728.	3.7	11
119	Prevalence, Correlates, and Temporal Trends in Antiarrhythmic Drug Use at Discharge After Implantable Cardioverter Defibrillator Placement (from the National Cardiovascular Data Registry) Tj ETQq1 1 0.	.78 <b>43</b> 14 rg	gBT‡Øverlock
120	Frequency and Effects of Excess Dosing of Anticoagulants in Patients â‰\$5ÂYears With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). American Journal of Cardiology, 2015, 116, 1-7.	1.6	11
121	Hospital Performance on Percutaneous Coronary Intervention Process and Outcomes Measures. Journal of the American Heart Association, 2017, 6, .	3.7	11
122	Development and validation of a simple risk score to predict 30â€day readmission after percutaneous coronary intervention in a cohort of medicare patients. Catheterization and Cardiovascular Interventions, 2017, 89, 955-963.	1.7	11
123	Variation in propofol induction doses administered to surgical patients over age 65. Journal of the American Geriatrics Society, 2021, 69, 2195-2209.	2.6	11
124	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S.ÁPractice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions, 2021, 14, 2344-2349.	2.9	11
125	Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC: Cardiovascular Interventions, 2022, 15, 950-961.	2.9	11
126	Temporal Trends in and FactorsÂAssociated With Use of Single-ÂVersusÂDual-Coil Implantable Cardioverter-Defibrillator Leads. JACC: Clinical Electrophysiology, 2017, 3, 612-619.	3.2	10

Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Calms Data, Journal of the American Heart Association, 2020, 9, e013606.  Tronds in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Parisms Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Rephrology:  4.5 10 CASN, 2020, 15, 1622-1630  Can machine learning complement traditional medical device surveillance? A case-study of dial-chamber implantable cardioverter® Ampundadidefibrillators. Medical Devices Evidence and Research, 2017, Volume 10, 165-168.  130 Distribution of Industry Psymerts. Among Medical Directors of Cathetavitation and Electrophysiology Liberatorias Promotite Top 100 US Hospitals: JAMA Internal Medicine, 2019, 179, 1282.  131 Distribution of Frontier on the Inglith Supprials: JAMA Internal Medicine, 2019, 179, 1282.  132 Liberation Myreacrital Infection With Multivessel Coronary Artery Disease in the United States. JAMA Cardiology, 2010, 6, 574.  133 October 100 COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes of Subcuttaneous or Transversions Implantable Cardiovertere-Defibrillators in October States. Jama Cardioverse Continuing Cardiovertere Defibrillators in October Patients, Journal of the American College of Cardiovertere-Defibrillator Use In U.S. Individuals. Journal of the American Certaines Society, 2011, 59, 1589-1595.  134 Ago Differences in Primary Prevention Implantable Cardiovertere-Defibrillator Use In U.S. Individuals. Journal of the American Certaines Society, 2011, 59, 1589-1595.  135 Activity Common of Subcuttaneous Commons Implantation in Patients With Art of Fibrillation and Converse Art Analysis from the Rational Cardioverteria Defibrillator (Common State) (Cardioverteria) (Card	#	Article	IF	CITATIONS
Patients Undergoing Long-Term Dialysis, Clinical Journal of the American Society of Nephrology:  Clash, 2020, 15, 1622-1630.  Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardiovarier kampundashyde/fibrillators. Medical Devices: Evidence and Research, 2017, Volume 10, 165-188.  Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals, JaMak Internal Medicine, 2019, 179, 1282.  130 Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals, JaMak Internal Medicine, 2019, 179, 1282.  131 ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States.  132 Jama Cathetic Myocardial Infarction With Multivessel Coronary Artery Disease in the United States.  133 Journal Of Covernal of Medicine, 2021, 134, 1380-1388.e3.  134 Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter Defibrillators in Older Patients, Journal of the American College of Cardiology, 2022, 79, 1050-1059.  135 Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter Defibrillators in Older Patients, Journal of the American College of Cardiology, 2022, 79, 1050-1059.  136 Age Differences in Primary Prevention Implantable Cardioverter&EDefibrillator Use in U.S. Individuals, Journal of the American Geristrics Society, 2011, 59, 1589-1595.  135 Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR) csup-34 states of Administrative Claims of the American Heart Association, 2019, 8, e010373.  136 Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes, Journal of the American Heart Association, 2019, 8, e010373.  137 8 Adelption of the transradial approach for percutaneous coronary intervention and rates of vascular complexitors in New Yo	127	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. Journal of the American Heart Association, 2020, 9, e013606.	3.7	10
dual-chamber implantable cardioverter&ampridashydefibrillators. Medical Devices: Evidence and Research, 2017, Volume 10, 165-188.  Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals. JAMA Internal Medicine, 2019, 179, 1282.  Temporal Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for Stevention Mycordial Infarction With Multivessel Coronary Artery Disease in the United States.  6.1 9  Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e.3.  132	128	Patients Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology:	4.5	10
Iaboratories From the Top 100 US Hospitals, JAMA Internal Medicine, 2019, 179, 1282.  Iamproral Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for Stephenotan Myocardial Infarction With Multivessel Coronary Artery Disease in the United States.  Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes, American Journal of Medicine, 2021, 134, 1380-1388.e.3.  132	129	dual-chamber implantable cardioverter–defibrillators. Medical Devices: Evidence and	0.8	9
STELevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States.  Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e.3.  Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Oider Patients. Journal of the American College of Cardiology, 2022, 79, 1050-1059.  Age Differences in Primary Prevention Implantable Cardioverterace Defibrillator Use in U.S. Individuals. Journal of the American Geriatrics Society, 2011, 59, 1589-1595.  Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR) scupp-& (supp.) Journal of the American Heart Association, 2015, 4.  Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  3.7 8  Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  Adoption of the transradial approach for percutaneous coronary Intervention and rates of vascular complications following transfernoral procedures: Insights from -scp-NCDR-/scp-, Catheterization and Cardiovascular Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillator and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular 2.2 6  A	130		5.1	9
Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e3.  Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. Journal of the American College of Cardiology, 2022, 79, 1050-1059.  Age Differences in Primary Prevention Implantable Cardioverteractoefibrillator Use in U.S. Individuals. Journal of the American Geriatrics Society, 2011, 59, 1589-1595.  Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR) 3.7 8 csup x 4 c/sup. Journal of the American Heart Association, 2015, 4, .  136 Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  137 Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  138 PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  2.8 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from cscp NCDRx/scp>. Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary 7  Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure, JAMA Cardiology, 2020, 5, 643-651.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular  2.2 6  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	131	ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States.	6.1	9
Age Differences in Primary Prevention Implantable Cardioverterâ-EDefibrillator Use in U.S. Individuals.  Journal of the American Geriatrics Society, 2011, 59, 1589-1595.  Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)  Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)  Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  3.7 8  138 Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  138 PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  2.8 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <a href="scrp">scrp</a> NCDR/scp>. Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.  40 Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  141 Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  42 Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	132	Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e3.	1.5	9
Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)  Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  3.7 8  136 Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  3.7 8  137 Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  138 PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  2.8 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <a href="scp">scp</a> NCDR/scp>. Catheterization 1.7 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <a href="scp">scp</a> NCDR/scp>. Catheterization 1.7 7  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  140 Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable 2.2 6  Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular 2.2 6  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	133		2.8	9
Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)  (sup) A (sup) Journal of the American Heart Association, 2015, 4.  Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  3.7 8  Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  2.8 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from (scp>NCDR*/scp>. Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular 2.2 6  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	134	Age Differences in Primary Prevention Implantable Cardioverterâ€Defibrillator Use in U.S. Individuals. Journal of the American Geriatrics Society, 2011, 59, 1589-1595.	2.6	8
Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.  137 Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  138 PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  2.8 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <scp>NCDR</scp> . Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.  140 Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  5.9 7  Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	135	Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)	3.7	8
Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.  138 PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.  2.8 7  Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <scp>NCDR</scp> . Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.  140 Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  5.9 7  141 Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	136	Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.	3.7	8
Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <scp>NCDR</scp> . Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.  140 Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  141 Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  142 Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  148 Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	137		1.6	8
complications following transfemoral procedures: Insights from <scp>NCDR</scp> . Catheterization  1.7 7 and Cardiovascular Interventions, 2018, 92, 835-841.  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.  Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	138	PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.	2.8	7
Practice. JAMA Network Open, 2019, 2, e1913553.  Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.  Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	139	complications following transfemoral procedures: Insights from <scp>NCDR</scp> . Catheterization	1.7	7
Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	140		5.9	7
Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .  Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients	141		6.1	7
Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal, 2022, 246, 21-31.	142	Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular	2.2	6
	143	Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal, 2022, 246, 21-31.	2.7	6

Coronary Venous Dissection from Left Ventricular Lead Placement During Cardiac Resynchronization
Therapy With Defibrillator Implantation and Associated in-Hospital Adverse Events (from the NCDR ICD) Tj ETQq0 QLGrgBT / Osverlock 10

#	Article	IF	CITATIONS
145	Quadripolar versus bipolar leads in cardiac resynchronization therapy: An analysis of the National Cardiovascular Data Registry. Heart Rhythm, 2020, 17, 81-89.	0.7	5
146	Impact of insurance status on ICD implantation practice patterns: Insights from the NCDR ICD registry. American Heart Journal, 2021, 235, 44-53.	2.7	5
147	Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional Capabilities. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 882-888.	2.2	4
148	Comparison of Inhospital Outcomes and Hospitalization Costs of Peripheral Angioplasty and Endovascular Stenting. American Journal of Cardiology, 2015, 116, 634-641.	1.6	4
149	Association of Physician Specialty With Long-Term Implantable Cardioverter-Defibrillator Complication and Reoperations Rates. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005374.	2.2	4
150	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. American Heart Journal, 2020, 222, 93-104.	2.7	4
151	Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain–MI Registry. International Journal of Cardiology, 2020, 304, 14-20.	1.7	4
152	Prevalence, predictors and complications with defibrillation threshold testing in pediatric patients: Results from the NCDR. International Journal of Cardiology, 2020, 305, 44-49.	1.7	4
153	Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal, 2021, 233, 59-67.	2.7	4
154	Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project. Circulation: Cardiovascular Interventions, 2021, 14, e010323.	3.9	4
155	Living in the Readmission Era. Circulation: Cardiovascular Interventions, 2014, 7, 9-10.	3.9	3
156	More Than One Way to Close the GenderÂGap. Journal of the American College of Cardiology, 2018, 71, 2133-2135.	2.8	3
157	Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes. Heart Rhythm, 2020, 17, 1878-1886.	0.7	3
158	Sex Differences in 1â€Year Health Status Following Percutaneous Coronary Intervention in Patients Without Acute Myocardial Infarction: Results From the China PEACE Prospective Study. Journal of the American Heart Association, 2020, 9, e014421.	3.7	3
159	Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDRâ€ICD Registry. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1897-1906.	1.2	3
160	Trends in Use of Single- vs Dual-Chamber Implantable Cardioverter-Defibrillators Among Patients Without a Pacing Indication, 2010-2018. JAMA Network Open, 2022, 5, e223429.	5.9	3
161	Baby or Bathwater?. Circulation, 2013, 128, 1177-1178.	1.6	2
162	Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy. Journal of the American Heart Association, 2015, 4, e002009.	3.7	2

#	Article	IF	CITATIONS
163	Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes. JAMA Internal Medicine, 2015, 175, 1988.	5.1	2
164	Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011). Catheterization and Cardiovascular Interventions, 2016, 88, 605-616.	1.7	2
165	Response to Letter Regarding Article, "Temporal Trends in Percutaneous Coronary Intervention Appropriateness: Insights From the Clinical Outcomes Assessment Program― Circulation, 2016, 133, e424.	1.6	2
166	The bleeding risk treatment paradox at the physician and hospital level: Implications for reducing bleeding in patients undergoing percutaneous coronary intervention. American Heart Journal, 2022, 243, 221-231.	2.7	2
167	Defibrillation Safety Margin Testing in Patients With Congenital Heart Disease. JACC: Clinical Electrophysiology, 2021, 7, 1145-1154.	3.2	2
168	Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. Catheterization and Cardiovascular Interventions, 2020, 96, 1213-1221.	1.7	2
169	Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverterâ€Defibrillator Generator Changes. Journal of the American Heart Association, 2022, 11, .	3.7	2
170	Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 279-288.	1.3	1
171	Utilization Effects of the Affordable Care Act on Implantable Cardioverter-Defibrillator Therapy. Journal of the American College of Cardiology, 2020, 75, 1714-1717.	2.8	1
172	Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry). American Journal of Cardiology, 2021, 155, 64-71.	1.6	1
173	Changes in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2022, 38, 1361-1369.	1.5	1
174	A Fresh Perspective on Atrial Fibrillation $\hat{a}$ —. Journal of the American College of Cardiology, 2016, 68, 905-907.	2.8	0
175	Accounting for Nonadherence. Circulation, 2018, 137, 2139-2141.	1.6	0
176	Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry). American Journal of Cardiology, 2020, 133, 182-184.	1.6	0
177	Characteristics of cardiac catheterization laboratory directors at the 2017 U.S. News & World Report top 100 U.S. cardiovascular hospitals. Catheterization and Cardiovascular Interventions, 2021, 97, E624-E626.	1.7	0
178	Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. JAMA Network Open, 2021, 4, e2035470.	5.9	0
179	Trends in ICD Implantations and In-Hospital Outcomes after DOJ Investigation. Journal of Cardiac Failure, 2021, , .	1.7	0
180	Hospital Characteristics and Early Enrollment Trends in the American College of Cardiology Voluntary Public Reporting Program. JAMA Network Open, 2022, 5, e2147903.	5.9	0

#	Article	lF	CITATIONS
181	Title is missing!. , 2020, 15, e0238829.		O
182	Title is missing!. , 2020, 15, e0238829.		0
183	Title is missing!. , 2020, 15, e0238829.		O
184	Title is missing!. , 2020, 15, e0238829.		0